Here we demonstrate that PBRM1 loss in ccRCC is associated with increased sensitivity to direct and indirect MCL1 inhibition, highlighting MCL1 and CDK9 inhibitors like PRT1419 and PRT2527 as potential therapeutic options for this genetically defined patient subset with unmet need. The gene discussed is MCL1; the disease is nonpapillary renal cell carcinoma.